Tempe, AZ, June 6, 2019 – SDC is excited to announce that our team will present “Artificial Intelligence and Machine Learning: Innovations in Clinical Trial Data Automation” on Monday, June 24 at 5:30pm in the DIA Innovation Theater. With a focus toward achieving faster time to market, reducing R&D costs, and increasing clinical trial success rates, Artificial Intelligence (AI) and Machine Learning (ML) capabilities are quickly becoming the next frontier in clinical research. In this presentation, SDC will share an overview of AI/ML applications in clinical trials, a case study featuring AI/ML deployment in clinical data services, and several lessons learned to help you integrate AI/ML capabilities in your clinical trials.
To register for DIA as a VIP guest of SDC, please visit www.DIAglobal.org/VIPguest and use promo code VIP19080 for $100 off your DIA 2019 registration.
Artificial Intelligence and Machine Learning: Innovations in Clinical Trial Data Automation
Monday, June 24 at 5:30 PM – 6:00 PM, DIA Innovation Theater
Presented by SDC
About the Speakers
Richard B. Abelson, Ph.D.
President & Chief Executive Officer
Dr. Richard Abelson, President & CEO of Statistics & Data Corporation (SDC), founded the company in November of 2005. Prior to SDC’s inception, Richard served on the Board of Directors of Ora, Inc. (www.oraclinical.com) for over 10 years. Richard holds a Ph.D. in Industrial Engineering with a focus on applied statistics, quality, and reliability engineering from Arizona State University (ASU), a Master of Science in Industrial Engineering focused in Operations Research and Production Systems (ASU) and a Bachelor of Science in Engineering in Industrial Engineering (ASU), and is certified as a Six Sigma Black Belt. He is a member of DIA, ARVO and CDISC.
Dale W. Usner, Ph.D.
Chief Scientific Officer & Senior Vice President, Strategic Scientific Consulting
Dr. Dale Usner joined SDC in September 2011 and currently serves as CSO and Sr. VP, Strategic Scientific Consulting. Prior to joining SDC, he lead statistics and data management departments at AVI BioPharma, ZymoGenetics, and Bausch & Lomb, Inc. He maintains an array of therapeutic area expertise, including ophthalmic pharmaceuticals and devices, oncology, neurology, gastrointestinal, and anti-viral/anti-infective. Dale has a breadth of regulatory body meeting experience with the FDA, PMDA, and EMA, including involvement in advisory committee meetings. Dale holds a Ph.D. in Statistics from Oregon State University, a MS in Statistics from Carnegie Mellon University, and a BS in Mathematics from Dickinson College.
